TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07351045: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 2000 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,078,840

Rescue Site Savings

+$7,307,320

Unlock Full NCT07351045 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07351045 Rescue Dossier →